Abstract
We report here the draft genomes of two drug (fluoroquinolone)-resistant clinical isolates of Pseudomonas aeruginosa obtained from the corneal scrapings of keratitis patients from India. The two annotated genomes are 6.31 Mb and 6.41 Mb in size. These genomes are expected to facilitate the identification and understanding of the genes associated with acquired multidrug resistance.
Highlights
We report here the draft genomes of two drug-resistant clinical isolates of Pseudomonas aeruginosa obtained from the corneal scrapings of keratitis patients from India
The availability of whole-genome information of pathogens can help in unraveling the genetics/mechanism(s) of acquired drug resistance
The P7-L633/96 genome has 72 contigs, with a genome size of 6.41 Mb, an N50 of 108,322 bp, and 65.97% GϩC content. Both genomes were submitted to Rapid Annotations using Subsystems Technology (RAST) and the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) for annotation
Summary
We report here the draft genomes of two drug (fluoroquinolone)-resistant clinical isolates of Pseudomonas aeruginosa obtained from the corneal scrapings of keratitis patients from India. Pseudomonas aeruginosa is a Gram-negative bacterial pathogen associated with a variety of infections [1]. The emergence of multidrug resistance in P. aeruginosa isolates has been increasingly documented worldwide. In recent years, a number of clinical P. aeruginosa isolates have shown reduced susceptibilities or resistances to fluoroquinolones [3, 4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
